GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085

Biochemical Pharmacology

Volumn 93, Issue 3, 2015, Pages 370-379

  Garcia De Lucas, A ^a   Ahring, P K ^b,c   Larsen, J S ^b   Rivera Arconada, I ^a   Lopez Garcia, J A ^a   Mirza, N R ^b   Munro, G ^d  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Saniona A S   (Denmark)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NEUROSEARCH A S   (Denmark)

Author keywords

Analgesia; Central sensitization; Hyperalgesia; Pain; Spinal inhibition; Wind up

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; BRETAZENIL; CARRAGEENAN; DIAZEPAM; UNCLASSIFIED DRUG; [2 [3 [5 (2 HYDROXYPROPAN 2 YL) 1H 1,3 BENZODIAZOL 1 YL]PHENYL]BENZONITRILE]; [2 [3 [8 FLUORO 7 (2 HYDROXYPROPAN 2 YL)IMIDAZO[1,2 A]PYRIDIN 3 YL]PHENYL]BENZONITRILE]; [4 CHLORO 3 [6 [5 (2 HYDROXYPROPAN 2 YL) 1H 1,3 BENZODIAZOL 1 YL]PYRIDIN 2 YL]BENZONITRILE]; [5 [[[7 TERT BUTYL 3 (2 FLUOROPHENYL)[1,2,4]TRIAZOLO[4,3 B]PYRIDAZIN 6 YL]OXY]METHYL] 1 ETHYL 1H[1,2,4 ]TRIAZOLE]; 4 AMINOBUTYRIC ACID A RECEPTOR; 4-CHLORO-3-(6-(5-(2-HYDROXYPROPAN-2-YL)-1H-1,3-BENZODIAZOL-1-YL)PYRIDIN-2-YL)BENZONITRILE; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; GABRA5 PROTEIN, HUMAN; PYRIDINE DERIVATIVE;

ADULT; ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DORSAL ROOT; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ELECTROPHYSIOLOGY; EX VIVO STUDY; FEMALE; HYPERALGESIA; INFLAMMATORY PAIN; MALE; MONOSYNAPTIC REFLEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; INFLAMMATION; NEWBORN; ORGAN CULTURE TECHNIQUE; PAIN; PAIN MEASUREMENT; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SPINAL ROOT; SPRAGUE DAWLEY RAT; WISTAR RAT; XENOPUS LAEVIS;

ALLOSTERIC REGULATION; ANIMALS; ANIMALS, NEWBORN; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GABA MODULATORS; HUMANS; HYPERALGESIA; INFLAMMATION; MALE; ORGAN CULTURE TECHNIQUES; PAIN; PAIN MEASUREMENT; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, GABA-A; SPINAL NERVE ROOTS; XENOPUS LAEVIS;

EID: 84921848063     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.12.010     Document Type: Article

References (45)

1. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2002;2:795-816.
2. Ma W, Saunders PA, Somogyi R, Poulter MO, Barker JL. Ontogeny of GABAA receptor subunit mRNAs in rat spinal cord and dorsal root ganglia. J Comp Neurol 1993;338:337-59.
3. Paul J, Zeilhofer HU, Fritschy JM. Selective distribution of GABA(A) receptor subtypes in mouse spinal dorsal horn neurons and primary afferents. J Comp Neurol 2012;520:3895-911.
4. Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008;451:330-4.
5. Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU. Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain 2009;141:233-8.
6. Nickolls S, Mace H, Fish R, Edye M, Gurrell R, Ivarsson M, et al. A comparison of the α2/3/5 selective positive allosteric modulators L-838,417 and TPA023 in preclinical models of inflammatory and neuropathic pain. Adv Pharmacol Sci 2011;608912.
7. Reichl S, Augustin M, Zahn PK, Pogatzki-Zahn EM. Peripheral and spinal GABAergic regulation of incisional pain in rats. Pain 2012;153:129-41.
8. Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, et al. Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimi-dazol- 1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2008;327:969-81.
9. Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ, Edwankar R, et al. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology 2011;60:626-32.
10. Paul J, Yévenes GE, Benke D, Lio AD, Ralvenius WT, Witschi R, et al. Anti-hyperalgesia by α2-GABA(A) receptors occurs via a genuine spinal action and does not involve supraspinal sites. Neuropsychopharmacology 2014;39:477-87.
11. Mirza NR, Munro G. The role of GABA-A receptor subtypes as analgesic targets. Drug News Perspect 2010;23:351-60.
12. Maubach K. GABAA receptor subtype selective cognition enhancers. Curr Drug Targets CNS Neurol Disord 2003;2:233-9.
13. Hedo G, Laird JM, Lopez-Garcia JA. Time-course of spinal sensitization following carrageenan-induced inflammation in the young rat: a comparative electrophysiological and behavioural study in vitro and in vivo. Neuroscience 1999;92:309-18.
14. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011;152(3):S2-15.
15. Zeilhofer HU, Wildner H, Yévenes GE. Fast synaptic inhibition in spinal sensory processing and pain control. Physiol Rev 2012;92:193-235.
16. Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, et al. NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J Pharmacol Exp Ther 2008;327:954-68.
17. Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, et al. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 2006;316:410-22.
18. Atack JR, Wong DF, Fryer TD, Ryan C, Sanabria S, Zhou Y, et al. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. J Pharmacol Exp Ther 2010;332:17-25.
19. Dias R, Sheppard WF, Fradley RL, Garrett EM, Stanley JL, Tye SJ, et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 2005;25:10682-88.
20. A receptors as novel targets. Trends Pharmacol Sci 2009;30:453-9.
21. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-10.
22. Lopez-Garcia JA, Laird JM. Central antinociceptive effects of meloxicam on rat spinal cord in vitro. Neuroreport 1998;9:647-51.
23. Hedo G, Lopez-Garcia JA. Alpha-1A adrenoceptors modulate potentiation of spinal nociceptive pathways in the rat spinal cord in vitro. Neuropharmacology 2001;41:862-9.
24. Yaksh TL, Ozaki G, McCumber D, Rathbun M, Svensson C, Malkmus S, et al. An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol 2001;90:2386-402.
25. Munro G, Erichsen HK, Rae MG, Mirza NR. A question of balance - positive versus negative allosteric modulation of GABA(A) receptor subtypes as a driver of analgesic efficacy in rat models of inflammatory and neuropathic pain. Neuropharmacology 2011;61:121-32.
26. Hansen RR, Erichsen HK, Brown DT, Mirza NR, Munro G. Positive allosteric modulation of GABA-A receptors reduces capsaicin-induced primary and secondary hypersensitivity in rats. Neuropharmacology 2012;63:1360-7.
27. van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 1996;41:565-73.
28. Rivera-Arconada I, Martinez-Gomez J, Lopez-Garcia JA. M-current modulators alter rat spinal nociceptive transmission: an electrophysiological study in vitro. Neuropharmacology 2004;46:598-606.
29. Torebjork HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol 1992;448:765-80.
30. Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced diffuse noxious inhibitory control (DNIC)-like effect in humans. Pain 2009;144:16-9.
31. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993;52:259-85.
32. Henry JL, Yashpal K, Pitcher GM, Coderre TJ. Physiological evidence that the 'interphase' in the formalin test is due to active inhibition. Pain 1999;82:57-63.
33. Munro G. Dopamine D(1), D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test. Eur J Pharmacol 2007;57:66-74.
34. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413:203-10.
35. Munro G, Hansen RR, Erichsen HK, Timmermann DB, Christensen JK, Hansen HH. The a7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat. Br J Pharmacol 2012;167:421-35.
36. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293-9.
37. A receptor modulation: potential to deliver novel pain medicines? Eur J Pharmacol 2013;716:17-23.
38. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987;26:1235-8.
39. Hu XD, Ge YX, Hu NW, Zhang HM, Zhou LJ, Zhang T, et al. Diazepam inhibits the induction and maintenance of LTP of C-fiber evoked field potentials in spinal dorsal horn of rats. Neuropharmacology 2006;50:238-44.
40. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000;3:587-92.
41. Povedano M, Gascon J, Galvez R, Ruiz M, Rejas J. Cognitive function impairment in patients with neuropathic pain under standard conditions of care. J Pain Symptom Manage 2007;33:78-89.
42. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796-800.
43. de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 2007;21:374-83.
44. de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, et al. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 2008;22:24-32.
45. de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol 2009;23:625-32.